



# MEMORANDUM

Agenda Item 15(C)1 Supplement

---

TO: Honorable Chairman Jean Monestime, and  
Members, Board of County Commissioners

DATE: April 5, 2016

FROM: Honorable Harvey Ruvin, Clerk  
Circuit and County Courts

SUBJECT: Supplement information regarding  
the appointment of Virginia Mirabal  
to serve as a member of the Small  
Business Enterprise Construction  
Advisory Board

Christopher Agrippa, Director  
Clerk of the Board Division

---

Pursuant to Resolution No. R-636-14, adopted on July 1, 2014, requires that the Office of the Commission Auditor (OCA) complete a background research on applicants being considered to serve on County Boards and Trusts that require nominations and/or appointments by the Board of County Commissioners (BCC).

Attached for your information and review is the Commission Auditor's findings regarding Item 15(C)1 on today's agenda regarding the appointment of Virginia Mirabal to serve as a member of the Small Business Enterprise Construction Advisory Board.

CA/fcd  
Attachment



**BOARD OF COUNTY COMMISSIONERS  
OFFICE OF THE COMMISSION AUDITOR**

**MEMORANDUM**

**TO:** Honorable Chairman Jean Monestime  
and Members, Board of County Commissioners

**FROM:** Charles Anderson  
Commission Auditor 

**DATE:** April 5, 2016

**SUBJECT:** **Appointment of Virginia Mirabal to serve as a member of the Small Business Enterprise Construction Advisory Board**

---

Resolution No. R-636-14, adopted on July 1, 2014, requires that the Office of the Commission Auditor (OCA) complete a background research on applicants being considered to serve on County Boards and Trusts that require nominations and/or appointments by the Board of County Commissioners (BCC).

In accordance with that Resolution, we are providing this report as a supplement to the BCC Agenda Item 15(C)1.

Pursuant to R-636-14, the OCA completed background research regarding BCC Agenda Item 15(C)1, Appointment of Virginia Mirabal to serve as a member of the Small Business Enterprise Construction Advisory Board and there were no adverse findings that came to our attention.